<ul>
	<li><strong>Bone Loss</strong>: Dose- and duration-dependent decreases in bone mineral density (BMD) that may not be completely reversible. Assess BMD in women with additional risk factors for bone loss</li>
	<li><strong>Reduced Ability to Recognize Pregnancy</strong>: Elagolix may alter menstrual bleeding, which may reduce the ability to recognize pregnancy. Perform testing if pregnancy is suspected. Discontinue if pregnancy is confirmed</li>
	<li><strong>Suicidal Ideation and Mood Disorders</strong>: Advise patients to seek medical attention for suicidal ideation, suicidal behavior, new onset or worsening depression, anxiety, or other mood changes</li>
	<li><strong>Hepatic Transaminase Elevations</strong>: Dose-dependent elevations in serum alanine aminotransferase (ALT). Counsel patients on signs and symptoms of liver injury</li>
	<li><strong>Potential for Reduced Efficacy with Estrogen-Containing Contraceptives</strong>: Use non-hormonal contraception during treatment and for one week after discontinuing Elagolix.</li>
</ul>